Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects With Cystic Fibrosis and the G551D Mutation
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Dec 2021
Price :
$35
*
At a glance
- Drugs Ivacaftor (Primary)
- Indications Cystic fibrosis
- Focus Registrational; Therapeutic Use
- Acronyms STRIVE
- Sponsors Vertex Pharmaceuticals
- 08 Oct 2015 According to a Vertex media release, post-hoc analysis of this, PERSIST and ENVISION studies was presented at the 29th Annual North American Cystic Fibrosis Conference
- 21 Oct 2013 New trial record